291
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Venous plasma serotonin is not a proper biomarker for pulmonary arterial hypertension

, , , &
Pages 106-110 | Received 16 Oct 2013, Accepted 18 Jan 2014, Published online: 24 Feb 2014

References

  • Hoeper MM. Definition, classification, and epidemiology of pulmonary arterial hypertension. Semin Respir Crit Care Med. 2009;30:369–75.
  • Maclean MR, Dempsie Y. The serotonin hypothesis of pulmonary hypertension revisited. Adv Exp Med Biol. 2010;661:309–22.
  • Herve P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 1995;99:249–54.
  • Lee SL, Wang WW, Lanzillo JJ, Fanburg BL. Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol. 1994;266:L46–52.
  • Rothman RB, Ayestas MA, Dersch CM, Baumann MH. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation. 1999;100:869–75.
  • MacLean MR. Pulmonary hypertension and the serotonin hypothesis: where are we now?Int J Clin Pract Suppl. 2007;156:27–31.
  • Dumitrascu R, Kulcke C, Konigshoff M, Kouri F, Yang X, Morrell N, et al. Terguride ameliorates monocrotaline- induced pulmonary hypertension in rats. Eur Respir J. 2011;37:1104–18.
  • de Caestecker M. Serotonin signaling in pulmonary hypertension. Circ Res. 2006;1229–31.
  • Tyce GM. Origin and metabolism of serotonin. J Cardiovasc Pharmacol. 1990;16:S1–7.
  • Kereveur A, Callebert J, Humbert M, Herve P, Simonneau G, Launay JM, Drouet L. High plasma serotonin levels in primary pulmonary hypertension. Effect of long-term epoprostenol (prostacyclin) therapy. Arterioscler Thromb Vasc Biol. 2000;20:2233–9.
  • de Jong WH, Wilkens MH, de Vries EG, Kema IP. Automated mass spectrometric analysis of urinary and plasma serotonin. Anal Bioanal Chem. 2010;396:2609–16.
  • Lederer DJ, Horn EM, Rosenzweig EB, Karmally W, Jahnes M, Barst RJ, Kawut SM. Plasma serotonin levels are normal in pulmonary arterial hypertension. Pulm Pharmacol Ther. 2008;21:112–4.
  • Ulrich S, Huber LC, Fischler M, Treder U, Maggiorini M, Eberli FR, Speich R. Platelet serotonin content and transpulmonary platelet serotonin gradient in patients with pulmonary hypertension. Respiration. 2011;81:211–6.
  • Zeinali F, Fossmark R, Hauso O, Wiseth R, Hjertner O, Waldum HL. Serotonin in blood: Assessment of its origin by concomitant determination of beta-thromboglobulin (platelets) and chromogranin A (enterochromaffin cells). Scand J Clin Lab Invest. 2013;73:148–53.
  • Seferian A, Simonneau G. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?Eur Respir Rev. 2013;22:217–26.
  • Brand T, Anderson GM. The measurement of platelet-poor plasma serotonin:a systematic review of prior reports and recommendations for improved analysis. Clin Chem. 2011;57:1376–86.
  • Schulman LL, Grossman BA, Owen J. Platelet activation and fibrinopeptide formation in pulmonary hypertension. Chest. 1993;104:1690–3.
  • Fujiwara Y, Browne CP, Cunniff K, Goff SC, Orkin SH. Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1. Proc Natl Acad Sci USA. 1996;93:12355–8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.